Thursday, May 14, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

Talking DPC with Miss Tiffany Ryder

We speak with Miss Tiffany Ryder about her experiences treating patients in rural emergency departments and her thoughts on future trends in direct primary care.

Tiffany Ryder is an NFL Cheerleader turned Emergency Medicine PA and is passionate about facilitating access to affordable primary care. She is a founding partner of Direct Care Connect, a non-profit healthcare delivery model with a vision to provide direct primary care services to underserved and uninsured communities in the US. She writes and speaks frequently on her personal and clinical experiences highlighting the need for expanded access to patient education and services in these populations.

To learn more about her work, select the following link: https://www.tiffanyryder.com/

#tiffanyryder #direct #primary #care #concierge #medicine

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Leave a Reply

Your email address will not be published. Required fields are marked *

Videos

Policy Shift in Peptide Regulation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!